United States Patent 5,621,104
Graham, et al. Apr. 15, 1997
Useful in the prevention and treatment of hyper-androgenic disorders.
Inventors:
Donald W. Graham, William K. Hagmann
Assignee:
Merck & Co., Inc. (Rahway, NJ).
Appl. No:
522,350
Filed:
Sept. 5, 1995
Related U.S. Application Data:
Continuation of (including streamline cont.) Ser. No. 36,645, Mar. 24, 1993, abandoned.
Intl. Cl.: C07D 221/12, C07D 401/12
Current U.S. Cl.: 546/108; 514/298; 546/109
Field of Search: 546/108, 109; 514/298
Abstract:
The present invention provides for the preparation of compounds,namely, 3-phenanthridiNones and their derivatives and their unique ability to inhibit 5-alpha-reductase or their isozymes thereof in mammals enabling said compounds for treating hyperandrogenic conditions of acne, androgenicalopecia, male pattern baldness,female hirsutism,benign prostatic hyperplasia, prostatitis and prostatic cancer.
1 Claim, No Drawings
References Cited:
U.S. Patent Documents
2,227,876 Jan., 1941 Bolt 546/77
3,239,417 Mar., 1966 Ditullio et al. 514/284
3,264,301 Aug., 1966 Doorenboos et al. 546/77
3,285,918 Nov., 1966 Doorenboos et al. 544/245
3,567,733 Mar., 1971 Nomine et al. 546/79
4,220,775 Sept., 1980 Rasmusson et al. 546/77
4,317,817 Mar., 1982 Blohm et al. 514/150
4,377,584 Mar., 1983 Rasmusson et al. 514/284
4,596,812 Jun., 1986 Chidsey, III et al. 514/256
4,732,897 Mar., 1988 Cainelli et al. 514/228.2
4,760,071 Jul., 1988 Rasmusson et al. 514/284
4,845,104 Jul., 1989 Carlin et al. 514/284
4,859,681 Aug., 1989 Rasmusson et al. 514/284
4,882,319 Nov., 1989 Holt et al. 514/119
4,910,226 Mar., 1990 Holt et al. 514/573
5,247,091 Sept., 1993 Mueller-Lehar 546/105
Foreign Patent Documents
970692 Jul., 1975 CA
0004949 Oct., 1979 EP
0155096 Sept., 1985 EP
0200859 Nov., 1986 EP
0277002 Jun., 1988 EP
0289327 Nov., 1988 EP
0314199 May, 1989 EP
0343954 Nov., 1989 EP
0375344 Jun., 1990 EP
0375345 Jun., 1990 EP
0375347 Jun., 1990 EP
0375349 Jun., 1990 EP
1465544 Nov., 1965 FR
WO91/12261 Aug., 1991 WO
Other References
Campbell et al., Syn. Commun. (1979), vol. 9, pp. 471-476, “A Novel Synthesis . . . : An Intermediate Useful in Terpene Synthesis”.
Vila et al., Tet. Letters (1989), vol. 45, pp. 4951-4960, “Conformational Analysis of the 4a-Methyl Octahydrophenanthrene System”.
Iida et al., Heterocycles (1983), vol. 20, pp.227-230, “A New Synthesis of Phenanthridine Derivatives”.
Schultz et al., J. Am. Chem. Soc. (1978), vol. 100, pp. 2140-2149, “Heteroatom Directed Photoarylation. Synthetic Potential of the Heteroatom Sulfur”.
Neri et al., Endo. (1972), vol. 91, No. 2, pp. 427-437, “A Biological Profile of a Non-steroidal Antiandrogen, SCH 13521 . . . “.
Nayfeh et al., Steroids, vol. 14 (1969), pp. 269-283, “Metabolism of Progesterone by Rat Testicular Homogenates-III”.
Voight et al., Endo., vol. 92 (1973), p.1216, “The Antiandrogenic Action of 4-Androsten-3-one-17beta-Carboxylic Acid and its Methyl Ester on Hamster Flank Organ”.
Doorenbos et al., J. Pharm. Sci., vol. 62, No. 4 (1973), pp. 638-640, “Synthesis & Antimicrobial Properties of 17Beta-Isopentyloxy-4-Aza-5 Alpha-Androstane and the 4-Methyl Derivative”.
Doorenbos et al., J. Pharm. Sci., vol. 60, No. 8 (1971), pp. 1234-1235, “4,17 Alpha-Dimethyl-4-Aza-5 Alpha-Androstan-17 beta-ol Acetate & Related Azasteroids”.
Doorenbos et al., J. Pharm. Sci., vol. 63, No. 4 (1974), pp. 620-622, “Synthesis & Evaluation of Antimicrobial Properties of Amidinoazaandrostanes and Guanidinoazaandrostanes”.
Rasmusson et al., J. Med. Chem., vol. 29, No.11 (1986), pp. 2298-3115, “Aza Steroids: Structure-Activity Relationships . . . “.
Brooks et al., Prostate, vol. 9, No. 1 (1986), pp. 65-75, “Prostatic Effects Induced in Dogs by . . . 5 alpha-Reductase Inhibitors”.
Brooks et al., Steroids, vol. 47, No. 1 (1986), pp. 1-19, “5 Alpha-Reductase Inhibitory . . . Activities of Some 4-Aza-Steroids in the Rat”.
Liang et al., Endo., vol. 117, No. 2, (1986), pp. 571-579, “Species Differences in Prostatic Steroidal 5 Alpha-Reductases of Rat, Dog and Human”.
Rasmusson et al., J. Med. Chem., vol. 27, No. 12 (1984), pp. 1690-1701, “Azasteroids as Inhibitors of Rat Prostatic 5 Alpha-Reductase”.
Back et al., J. Org. Chem, vol. 46, No. 7 (1981), pp. 1442-1446, “N-Chloroazasteroids . . . “.
Liang et al., Chem. Abstracts, vol. 95, 109055j, “Inhibition of 5-Alpha-Receptor Binding . . . by a 4-Methyl-4-Aza-Steroid” (1985).
Kadohama et al., JNCL, vol. 74, No. 2 (Feb. 1985), pp. 475-481, “Retardation of Prostate Tumor Progression in the Noble Rat by 4-Methyl-4-Aza-Steroidal Inhibitors of 5 Alpha-Reductase”.
Andriole et al., The Prostate, vol. 10 (1987), pp. 189-197, “The Effect of 4MA . . . on the Growth of . . . Human Tumors . . . “.
Bingham et al., J. Endocr., vol. 57 (1973), pp. 111-121, “The Metabolism of Testosterone by Human Male Scalp Skin”.
Kedderis et al., Toxicol. Appl. Pharmacol., vol. 103 (1990), pp. 222-227, “Studies with Nitrogen-Containing Steroids . . . “.
Metcalf et al., Bioinorganic Chemistry, vol. 17 (1986), pp. 372-376, “Patent Inhibition of Human Steroid . . . by 3-Androstene-3-Carboxylic Acid”.
Levy et al., Biochemistry, vol. 29 (1990), pp. 2815-2824, “Inhibition of Rat Liver Steroid 5 Alpha-Reductase . . . “.
Holt et al., J. Med. Chem., vol. 33 (1990), pp. 943-950, “Steroidal A Ring Carboxylic Acids . . . “.
Levy et al., J. Steroid Biochem., vol. 34, No. 1-6 (1989), pp. 571-575, “Interaction Between Rat Prostatic 5 Alpha-Reductase . . . “.
Holt et al., J. Med. Chem., vol. 33 (1990), pp. 937-942, “Steroidal A Ring Aryl Carboxylic Acids . . . “.
Metcalf et al., TIPS (Dec. 1989), vol. 10, pp. 491-495, “Inhibitors of . . . 5 Alpha-Reductase in Benign Prostatic Hyperplasia . . . “.
Murphy et al., Steroids, vol. 35, No. 3 (Mar. 1980), pp. 1-7, “Effect of Estradiol on a . . . Binding Protein in the Uterus of the Mouse”.
Stone et al., Prostate, vol. 9 (1986), pp. 311-318, “Estrogen Formation in Human Prostatic Tissue . . . “.
Brooks et al., Steroids, vol. 47, No. 1 (1986), pp. 1-19, “5 Alpha-Reductase Inhibitory . . . Activities of Some 4-Azasteroids . . . “.
Labrie et al., Lancet, No. 8515 (1986), pp. 1095-1096, “Combination Therapy in Prostate Cancer”.
Rittmaster et al., J. Clin. Endocrin & Metab., vol. 55, No. 1 (1987), pp. 188-193, “The Effects of . . . a 5 Alpha-Reductase Inhibitor . . . “.
Diani et al., J. Clin. Endoc. & Metab., vol. 74, No. 2 (1990), pp. 345-350, “Hair Growth Effects of Oral Administration of Finasteride . . . “.
Bruchovsky et al., J. Clin. Endoc. Metab., vol. 67, No. 4 (1988), pp. 808-816, “Kinetic Parameters of 5 Alpha-Reductase Activity in Stroma & Epithelium of Normal, Hyperplastic & Carcinomatous Human Prostates”.
Hudson, J. Steroid Biochem., vol. 26, No. 3 (1987), pp. 349-353, “Comparison of Nuclear 5 Alpha-Reductase Activities in the Stromal and Epithelial Fractions of Human Prostatic Tissue”.
Moore et al., J. Biol. Chem., vol. 251, No. 19 (1976), pp. 5895-5900, “Steroid 5 Alpha-Reductase in Cultured Human Fibroblasts”.
Andersson et al., J. Biol. Chem., vol. 264, No. 27 (1989), pp. 16249-16255, “Expession Cloning & Regulation of Steroid 5 Alpha-Reductase, an Enzyme Essential for Male Sexual Differentiation”.
Andersson et al., Proc. Nat’l Acad. Science, vol. 87 (1990), pp. 3640-3644, “Structural & Biochemical Properties of Cloned and Expressed Human and Rat Steroid 5 Alpha-Reductases”.
Andersson et al., Nature, vol. 354 (Nov. 14, 1991), pp. 159-161, “Deletion of Steroid 5 Alpha-Reductase-2 Gene in Male Pseudohermaphroditism”.
Wilson, Biol. of Reproduction, vol. 46 (1992), pp. 168-173, “Syndromes of Androgen Resistance”.
Geldolf et al., Eur. J. Cancer, vol. 26, No. 2 (1990), pp. 188, “Enzyme Inhibitors in Hormone Dependent Prostate Cancer Growth”.
Geldolf et al., J. Cancer Res. Clin. Oncol., vol. 118 (1992), pp. 50-55, “Consideration of the Use of . . . 4MA . . . in Prostate Cancer Research”.
Brooks et al., The Prostate, vol. 18 (1991), pp. 215-227, “Effect of Castration, DES, Flutamide, and MK-906 on Growth of the Dunning Rat Prostatic Carcinoma”.
Jones et al., J. Med. Chem., vol. 36 (1993), pp. 421-423, “Nonsteroidal Inhibitors of Human Type 1 Steroid 5alpha-Reductase”.
Masubuchi et al., Eur. J. Pharm., vol. 183, No. 5 (1990), p. 1757, “Lack of DHT Inhibition . . . by Treatment of 4MA . . . “.
Primary Examiner: Rotman; Alan L.
Assistant Examiner: Rotman; A.
Attorney, Agent or Firm: Fitch; Catherine D., Winokur; Melvin
